/
ANL
$12.86-$0.23 (-1.76%)prev close
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$843.0M
64M shares
52-week range
$0.88 – $17.25
73% from low
Exchange
NASDAQ
ADRC
Change$-2.14
Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd is a clinical-stage company at the forefront of discovering and developing cancer therapies. The company is building a robust pipeline of drug candidates focused on two key areas where it believes it can make a difference RAS-targeting therapies: its is tackling RAS-driven cancers with AN9025, an oral pan-RAS(ON) inhibitor, and AN4035, a CEACAM5-targeting ADC delivering a potent pan-RAS(ON) inhibitor directly to tumors; Next-generation cancer immunotherapies: its candidates, AN8025 (a tri-functional fusion protein of alphaPD-L1 x CD86 variant x LAG3 variant), a T-cell and antigen-presenting cell modulator, and AN4005 (a first-in-class oral small-molecule PD-L1 inhibitor), are designed to activate cancer immunity in novel ways.
www.adlainortye.com- Employees
- 109
- IPO / List date
- Sep 29, 2023
Held by traders on TradeandTell
No one on the platform currently holds ANL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 66,000 | $456.7K |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded ANL yet.
